Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/ROCK2_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/ROCK2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/ROCK2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/ROCK2_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ROCK2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ROCK2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/ROCK2_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/ROCK2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ROCK2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ROCK2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001603210 | Cervix | CC | viral process | 109/2311 | 415/18723 | 5.40e-15 | 6.46e-12 | 109 |
GO:001081010 | Cervix | CC | regulation of cell-substrate adhesion | 69/2311 | 221/18723 | 8.57e-14 | 5.69e-11 | 69 |
GO:00315898 | Cervix | CC | cell-substrate adhesion | 96/2311 | 363/18723 | 1.48e-13 | 8.85e-11 | 96 |
GO:001905810 | Cervix | CC | viral life cycle | 87/2311 | 317/18723 | 2.20e-13 | 1.20e-10 | 87 |
GO:000701510 | Cervix | CC | actin filament organization | 109/2311 | 442/18723 | 4.92e-13 | 2.45e-10 | 109 |
GO:005254710 | Cervix | CC | regulation of peptidase activity | 112/2311 | 461/18723 | 6.70e-13 | 3.08e-10 | 112 |
GO:004586210 | Cervix | CC | positive regulation of proteolysis | 95/2311 | 372/18723 | 1.84e-12 | 6.86e-10 | 95 |
GO:005254810 | Cervix | CC | regulation of endopeptidase activity | 103/2311 | 432/18723 | 1.89e-11 | 5.14e-09 | 103 |
GO:009013210 | Cervix | CC | epithelium migration | 90/2311 | 360/18723 | 2.45e-11 | 6.11e-09 | 90 |
GO:00016679 | Cervix | CC | ameboidal-type cell migration | 110/2311 | 475/18723 | 2.66e-11 | 6.36e-09 | 110 |
GO:001063110 | Cervix | CC | epithelial cell migration | 89/2311 | 357/18723 | 3.72e-11 | 8.54e-09 | 89 |
GO:00085446 | Cervix | CC | epidermis development | 83/2311 | 324/18723 | 3.91e-11 | 8.54e-09 | 83 |
GO:003297010 | Cervix | CC | regulation of actin filament-based process | 96/2311 | 397/18723 | 4.00e-11 | 8.54e-09 | 96 |
GO:00071639 | Cervix | CC | establishment or maintenance of cell polarity | 63/2311 | 218/18723 | 4.25e-11 | 8.76e-09 | 63 |
GO:009013010 | Cervix | CC | tissue migration | 90/2311 | 365/18723 | 5.42e-11 | 1.05e-08 | 90 |
GO:00435884 | Cervix | CC | skin development | 71/2311 | 263/18723 | 8.04e-11 | 1.46e-08 | 71 |
GO:190290310 | Cervix | CC | regulation of supramolecular fiber organization | 92/2311 | 383/18723 | 1.49e-10 | 2.48e-08 | 92 |
GO:190382910 | Cervix | CC | positive regulation of cellular protein localization | 72/2311 | 276/18723 | 3.20e-10 | 4.46e-08 | 72 |
GO:01501159 | Cervix | CC | cell-substrate junction organization | 37/2311 | 101/18723 | 3.20e-10 | 4.46e-08 | 37 |
GO:007265910 | Cervix | CC | protein localization to plasma membrane | 73/2311 | 284/18723 | 4.95e-10 | 6.73e-08 | 73 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0513027 | Endometrium | EEC | Pathogenic Escherichia coli infection | 51/1237 | 197/8465 | 1.98e-05 | 2.28e-04 | 1.70e-04 | 51 |
hsa0520524 | Endometrium | EEC | Proteoglycans in cancer | 52/1237 | 205/8465 | 3.01e-05 | 3.19e-04 | 2.38e-04 | 52 |
hsa0431022 | Endometrium | EEC | Wnt signaling pathway | 40/1237 | 171/8465 | 1.37e-03 | 8.99e-03 | 6.70e-03 | 40 |
hsa0541727 | Endometrium | EEC | Lipid and atherosclerosis | 48/1237 | 215/8465 | 1.41e-03 | 9.07e-03 | 6.77e-03 | 48 |
hsa0481024 | Endometrium | EEC | Regulation of actin cytoskeleton | 49/1237 | 229/8465 | 3.20e-03 | 1.78e-02 | 1.33e-02 | 49 |
hsa0516325 | Endometrium | EEC | Human cytomegalovirus infection | 47/1237 | 225/8465 | 6.17e-03 | 3.12e-02 | 2.33e-02 | 47 |
hsa0436022 | Endometrium | EEC | Axon guidance | 39/1237 | 182/8465 | 7.78e-03 | 3.66e-02 | 2.73e-02 | 39 |
hsa0513136 | Endometrium | EEC | Shigellosis | 79/1237 | 247/8465 | 1.80e-12 | 3.95e-11 | 2.95e-11 | 79 |
hsa0453036 | Endometrium | EEC | Tight junction | 54/1237 | 169/8465 | 6.56e-09 | 1.27e-07 | 9.46e-08 | 54 |
hsa0513236 | Endometrium | EEC | Salmonella infection | 71/1237 | 249/8465 | 7.11e-09 | 1.30e-07 | 9.69e-08 | 71 |
hsa0452035 | Endometrium | EEC | Adherens junction | 36/1237 | 93/8465 | 8.57e-09 | 1.48e-07 | 1.11e-07 | 36 |
hsa0451034 | Endometrium | EEC | Focal adhesion | 58/1237 | 203/8465 | 1.61e-07 | 2.30e-06 | 1.71e-06 | 58 |
hsa0467036 | Endometrium | EEC | Leukocyte transendothelial migration | 36/1237 | 114/8465 | 2.97e-06 | 3.91e-05 | 2.91e-05 | 36 |
hsa0513036 | Endometrium | EEC | Pathogenic Escherichia coli infection | 51/1237 | 197/8465 | 1.98e-05 | 2.28e-04 | 1.70e-04 | 51 |
hsa0520534 | Endometrium | EEC | Proteoglycans in cancer | 52/1237 | 205/8465 | 3.01e-05 | 3.19e-04 | 2.38e-04 | 52 |
hsa0431032 | Endometrium | EEC | Wnt signaling pathway | 40/1237 | 171/8465 | 1.37e-03 | 8.99e-03 | 6.70e-03 | 40 |
hsa0541736 | Endometrium | EEC | Lipid and atherosclerosis | 48/1237 | 215/8465 | 1.41e-03 | 9.07e-03 | 6.77e-03 | 48 |
hsa0481034 | Endometrium | EEC | Regulation of actin cytoskeleton | 49/1237 | 229/8465 | 3.20e-03 | 1.78e-02 | 1.33e-02 | 49 |
hsa0516335 | Endometrium | EEC | Human cytomegalovirus infection | 47/1237 | 225/8465 | 6.17e-03 | 3.12e-02 | 2.33e-02 | 47 |
hsa0436032 | Endometrium | EEC | Axon guidance | 39/1237 | 182/8465 | 7.78e-03 | 3.66e-02 | 2.73e-02 | 39 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ROCK2 | SNV | Missense_Mutation | novel | c.3226N>C | p.Lys1076Gln | p.K1076Q | O75116 | protein_coding | deleterious(0) | probably_damaging(0.946) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ROCK2 | SNV | Missense_Mutation | rs747260728 | c.1715N>A | p.Arg572Gln | p.R572Q | O75116 | protein_coding | tolerated(0.38) | benign(0.065) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ROCK2 | SNV | Missense_Mutation | | c.3560N>A | p.Ser1187Asn | p.S1187N | O75116 | protein_coding | tolerated(0.16) | benign(0.097) | TCGA-AN-A0FL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ROCK2 | SNV | Missense_Mutation | | c.4091G>C | p.Arg1364Thr | p.R1364T | O75116 | protein_coding | deleterious(0.01) | benign(0.041) | TCGA-AR-A0TX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ROCK2 | SNV | Missense_Mutation | | c.1849N>C | p.Glu617Gln | p.E617Q | O75116 | protein_coding | tolerated(0.34) | benign(0.083) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
ROCK2 | SNV | Missense_Mutation | novel | c.2329N>C | p.Glu777Gln | p.E777Q | O75116 | protein_coding | tolerated(0.67) | benign(0.028) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
ROCK2 | SNV | Missense_Mutation | novel | c.186N>C | p.Leu62Phe | p.L62F | O75116 | protein_coding | deleterious(0.02) | probably_damaging(0.95) | TCGA-XX-A89A-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ROCK2 | insertion | Nonsense_Mutation | novel | c.2665_2666insCAATTTAACTATAATCCAA | p.Glu889AlafsTer3 | p.E889Afs*3 | O75116 | protein_coding | | | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ROCK2 | SNV | Missense_Mutation | novel | c.712A>C | p.Lys238Gln | p.K238Q | O75116 | protein_coding | deleterious(0) | probably_damaging(0.929) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ROCK2 | SNV | Missense_Mutation | | c.2719N>A | p.Glu907Lys | p.E907K | O75116 | protein_coding | deleterious(0) | probably_damaging(0.957) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
9475 | ROCK2 | KINASE, ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE | inhibitor | 178102655 | | |
9475 | ROCK2 | KINASE, ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE | | AR-12286 | VEROSUDIL | |
9475 | ROCK2 | KINASE, ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE | | BAY-613606 | CHEMBL541400 | |
9475 | ROCK2 | KINASE, ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE | | AST-487 | AST-487 | |
9475 | ROCK2 | KINASE, ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE | | THROMBIN | THROMBIN | 16720831 |
9475 | ROCK2 | KINASE, ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE | inhibitor | 178101973 | | |
9475 | ROCK2 | KINASE, ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE | | KD025 | | |
9475 | ROCK2 | KINASE, ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE | | VER-49009 | CHEMBL365617 | |
9475 | ROCK2 | KINASE, ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE | | Tricyclic compound 4 | | |
9475 | ROCK2 | KINASE, ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE | inhibitor | 310264692 | VEROSUDIL | |